JIANGSU GDK(SH:688670) Xin Lang Cai Jing·2025-09-23 02:38Group 1 - The core point of the news is the decline in the stock price of Jindike Biotech, which fell by 5.05% to 14.66 CNY per share, with a total market capitalization of 1.806 billion CNY [1] - Jindike Biotech, established on December 29, 2008, focuses on the research, production, and sales of human vaccines, with 100% of its revenue derived from vaccine products [1] - The trading volume for Jindike Biotech was 6.309 million CNY, with a turnover rate of 0.34% [1] Group 2 - The Qianhai Kaiyuan Fund holds a significant position in Jindike Biotech, with 13,700 shares representing 1.11% of the fund's net value, making it the fifth-largest holding [2] - The fund, named Qianhai Kaiyuan Strong Consensus 100 Strong Stocks (001849), has a total scale of 17.2629 million CNY and has achieved a year-to-date return of 10.03% [2] - Over the past year, the fund has recorded a return of 30.13%, ranking 3212 out of 3814 in its category [2] Group 3 - The fund manager of Qianhai Kaiyuan Strong Consensus 100 Strong Stocks is Yuan Yichun, who has been in the position for 3 years and 38 days [3] - The total asset size of the fund is 67.572 million CNY, with the best return during Yuan's tenure being -9.11% and the worst being -26.57% [3]